Tomohiro Higa Biography and Net Worth

Senior Vice President, Finance of Tenaya Therapeutics

Mr. Higa serves as Tenaya’s Senior Vice President, Finance and interim principal accounting officer. Mr. Higa joined Tenaya in 2020 as Vice President and the head of the Finance department, bringing more than 20 years of experience in finance-focused roles for biopharmaceutical companies. While at Tenaya, he led the establishment of key financial systems and processes, including the company’s transition from private to public, and he directed the company’s short and long-term financial planning activities.

Prior to Tenaya, Mr. Higa served as Senior Director, Finance at CytomX Therapeutics, Inc. and Senior Director, Finance at OncoMed Pharmaceuticals, Inc. From 2006 to 2014, he held various finance roles at the corporate headquarters and two site operations of Amgen Inc. Prior to Amgen, he served in financial planning and analysis (FP&A) focused roles at Abgenix, Inc. and Ventro Corporation (formerly Chemdex Corporation). Mr. Higa received his B.A. in economics from the University of Chicago and an M.B. A. from the University of Chicago Booth School of Business.

What is Tomohiro Higa's net worth?: The estimated net worth of Tomohiro Higa is at least $93.31 thousand as of May 18th, 2026. Mr. Higa owns 118,267 shares of Tenaya Therapeutics stock worth more than $93,313 as of July 23rd. This net worth approximation does not reflect any other assets that Mr. Higa may own. Learn More about Tomohiro Higa's net worth.
How do I contact Tomohiro Higa?: The corporate mailing address for Mr. Higa and other Tenaya Therapeutics executives is , , . Tenaya Therapeutics can also be reached via phone at 650-825-6990 and via email at [email protected]. Learn More on Tomohiro Higa's contact information.
Has Tomohiro Higa been buying or selling shares of Tenaya Therapeutics?: Tomohiro Higa has not been actively trading shares of Tenaya Therapeutics within the last three months. Most recently, Tomohiro Higa sold 1,485 shares of the business's stock in a transaction on Monday, May 18th. The shares were sold at an average price of $0.79, for a transaction totalling $1,173.15. Following the completion of the sale, the senior vice president now directly owns 118,267 shares of the company's stock, valued at $93,430.93. Learn More on Tomohiro Higa's trading history.
Who are Tenaya Therapeutics' active insiders?: Tenaya Therapeutics' insider roster includes Faraz Ali (CEO), and Tomohiro Higa (Senior Vice President, Finance). Learn More on Tenaya Therapeutics' active insiders.
Are insiders buying or selling shares of Tenaya Therapeutics?: In the last year, insiders at the sold shares 16 times. They sold a total of 8,631,961 shares worth more than $5,474,511.12. The most recent insider tranaction occured on May, 18th when CEO Faraz Ali sold 3,390 shares worth more than $2,678.10. Insiders at Tenaya Therapeutics own 2.5% of the company. Learn More about insider trades at Tenaya Therapeutics.
Information on this page was last updated on 5/18/2026.

Tomohiro Higa Insider Trading History at Tenaya Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/18/2026	Sell	1,485	$0.79	$1,173.15	118,267
2/17/2026	Sell	3,469	$0.64	$2,220.16	119,752
11/17/2025	Sell	1,367	$1.33	$1,818.11	93,971
8/18/2025	Sell	2,962	$1.25	$3,702.50	95,338
5/16/2025	Sell	1,390	$0.44	$611.60	98,300
3/10/2025	Sell	2,482	$0.54	$1,340.28	99,690

Tomohiro Higa Buying and Selling Activity at Tenaya Therapeutics

Tenaya Therapeutics Company Overview

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Today's Range

Now: $0.78

$0.77

$0.80

50 Day Range

MA: $0.78

$0.68

$0.94

2 Week Range

Now: $0.78

$0.53

$2.35

Volume

518,135 shs

Average Volume

3,873,437 shs

Market Capitalization

$169.91 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.83